# Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

> **NCT06317558** · — · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 4000 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Neoadjuvant immunotherapy
- **DRUG:** Other drugs for neoadjuvant treatment

## Key facts

- **NCT ID:** NCT06317558
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2034-12-31
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317558, "Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06317558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*